The Blueprint for Modern Medicine
To understand why companies are spending millions to send experiments into orbit, we first need to look at proteins. They are the complex molecular machines that drive virtually every process in our bodies. When they malfunction, they can cause diseases
like cancer, Alzheimer's, and muscular dystrophy. Many modern drugs work by targeting these specific proteins. To design an effective drug, scientists need a precise 3D blueprint of the target protein. This is achieved through a process called X-ray crystallography, which requires growing a highly ordered, three-dimensional crystal of that protein.
The Problem with Gravity
On Earth, growing a perfect protein crystal is incredibly difficult. The force of gravity causes two major problems: sedimentation and convection. As crystals form in a solution, their weight causes them to settle, introducing flaws. At the same time, density and temperature variations in the liquid create tiny currents, or convection, that buffet the growing crystal structure. These disturbances result in smaller, less-ordered crystals with defects. A flawed crystal produces a blurry blueprint, making it much harder for scientists to understand the protein's structure and design a drug that can interact with it perfectly.
The Microgravity Advantage
In the microgravity environment of a space station, these Earth-bound problems vanish. With no significant gravitational pull, heavy crystals don't sink, and convection currents are virtually eliminated. This calm, stable environment allows protein molecules to arrange themselves slowly and precisely into a larger, more uniform, and nearly flawless lattice structure. The result is a high-quality crystal that, when brought back to Earth and analyzed, can provide an unprecedentedly clear and detailed 3D model of the protein. This has been demonstrated in research for diseases ranging from Duchenne Muscular Dystrophy to various cancers.
The Commercial Pioneers in Orbit
For decades, this research was primarily the domain of national space agencies like NASA. Now, a new commercial frontier is opening up. Companies like Redwire Space and Varda Space Industries are at the forefront, developing dedicated platforms to crystallize pharmaceuticals in orbit. Redwire has developed the PIL-BOX facility for the International Space Station (ISS) and has partnered with pharmaceutical giants like Eli Lilly and Bristol Myers Squibb to conduct experiments. Varda is taking a different approach, launching its own unmanned capsules to manufacture crystals in orbit and return them to Earth, aiming to build a scalable off-world production line. These companies see a significant business opportunity in providing a unique service that is impossible to replicate on the ground.
From Space Crystals to Better Drugs
The real-world impact is already being seen. Research aboard the ISS helped pharmaceutical company Merck develop a new formulation of its cancer drug, Keytruda. By studying how the antibody crystallized in space, they gained insights that led to an FDA-approved version that can be administered as a simple injection instead of a time-consuming intravenous infusion. Beyond just understanding protein structures, growing crystals in space can also lead to better drug formulations. The uniform crystals created in microgravity can be used to develop more stable and more concentrated medicines, potentially improving their shelf-life and effectiveness.
